0:00
11:00
@ michaelsalzle Patients with diabetes and chronic disease are at high risk for kidney failure, cardiovascular events, and death. The FLOW trial looked at the safety and efficacy of semaglutide in patients with chronic disease and type 2 diabetes.
More episodes from "Healthspan"
Don't miss an episode of “Healthspan” and subscribe to it in the GetPodcast app.